CG200745 is an intravenous hydroxamate-based pan-HDAC inhibitor similar to vorinostat10 whose anti-proliferative effect has been demonstrated in several types of cancer cells, including prostate cancer, renal cell carcinoma, and colon cancer, either alone or in combination with other chemotherapy drugs. This evidence concerns the gene HDAC9 and cancer.